Candel Therapeutics Inc (CADL): Next-Year EPS Estimate 25.46%
As of 2026-08-13, Candel Therapeutics Inc (CADL) has a next-year EPS growth estimate of 25.46%. Featured in our EPS revision report on 2026-06-30.
On 2026-08-12, analyst consensus for CADL's next-year EPS growth shifted from 25.52% to 25.46% — a negative change of 0.06 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at -29.33%.
What's Driving This
The primary EPS revision was a downgrade, not an upgrade: on 2026-07-13 analysts lowered next-year EPS growth estimates from 38.14% to 25.52%, with the current estimate at 25.46%. Recent headlines on extended clinical benefit for CAN-2409 in localized prostate cancer at AUA 2026 and first quarter 2026 financial results do not clearly explain the estimate cut or a sustained upward revision trend. On the available data, the EPS estimate trajectory
Generated 2026-09-28 from news as of 2026-08-13
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 25.46%
- EPS growth this year
- -29.33%
- EPS next quarter (est)
- -$0.25
- Last price
- $11.26
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-13 | 25.46% | -29.33% | -$0.25 | $11.26 |
| 2026-08-12 | 25.46% | -29.33% | -$0.23 | $10.68 |
| 2026-08-11 | 25.52% | -29.33% | -$0.23 | $10.65 |
| 2026-08-10 | 25.52% | -29.33% | -$0.23 | $10.50 |
| 2026-08-09 | 25.52% | -29.33% | -$0.23 | $10.59 |
| 2026-08-07 | 25.52% | -29.33% | -$0.23 | $10.59 |
| 2026-08-06 | 25.52% | -29.33% | -$0.23 | $10.58 |
| 2026-08-05 | 25.52% | -29.33% | -$0.23 | $10.46 |
| 2026-08-04 | 25.52% | -29.33% | -$0.23 | $10.51 |
| 2026-08-03 | 25.52% | -29.33% | -$0.23 | $10.07 |
| 2026-08-02 | 25.52% | -29.33% | -$0.23 | $10.01 |
| 2026-07-31 | 25.52% | -29.33% | -$0.23 | $10.01 |
| 2026-07-30 | 25.52% | -29.33% | -$0.23 | $9.87 |
| 2026-07-29 | 25.52% | -29.33% | -$0.23 | $9.40 |
| 2026-07-28 | 25.52% | -29.33% | -$0.23 | $9.68 |
| 2026-07-27 | 25.52% | -29.33% | -$0.23 | $9.96 |
| 2026-07-26 | 25.52% | -29.33% | -$0.23 | $9.56 |
| 2026-07-24 | 25.52% | -29.33% | -$0.23 | $9.56 |
| 2026-07-23 | 25.52% | -29.33% | -$0.23 | $9.86 |
| 2026-07-22 | 25.52% | -29.33% | -$0.23 | $10.09 |
| 2026-07-21 | 25.52% | -29.33% | -$0.23 | $10.22 |
| 2026-07-20 | 25.52% | -29.33% | -$0.23 | $9.57 |
| 2026-07-19 | 25.52% | -29.33% | -$0.23 | $10.18 |
| 2026-07-17 | 25.52% | -29.33% | -$0.23 | $10.18 |
| 2026-07-16 | 25.52% | -29.33% | -$0.23 | $9.48 |
| 2026-07-15 | 25.52% | -29.33% | -$0.23 | $9.64 |
| 2026-07-14 | 25.52% | -29.33% | -$0.23 | $9.87 |
| 2026-07-13 | 25.52% | -29.33% | -$0.23 | $9.64 |
| 2026-07-12 | 38.14% | -28.17% | -$0.23 | $9.49 |
| 2026-07-09 | 38.14% | -28.17% | -$0.23 | $9.89 |
Reports Featuring CADL
Recent News
- Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual MeetingGlobeNewswire
- Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswire
Screen Performance
Aggregate stats across all 2082 tickers our top-EPS-revision screen has flagged over the past 198 days.
- Median return since detection
- -3.0%
- % of tickers in the green
- 43%
- Median return on winners
- +21.5%
- Large revisions captured
- 1886
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Candel Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-08-13, Candel Therapeutics Inc (CADL) has a next-year EPS growth estimate of 25.46%, based on analyst consensus.
When was the latest EPS estimate revision for CADL?▾
The most recent revision occurred on 2026-08-12, when analysts adjusted the next-year EPS growth estimate from 25.52% to 25.46%.
What sector and industry does Candel Therapeutics Inc belong to?▾
Candel Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CADL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Candel Therapeutics Inc (CADL) appears here because it was detected by our daily top-EPS-revision-performer screen.